ALS: edaravone found safe, effective in well-defined group
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Edaravone (Radicava) slowed the decline in function during 24 wk in patients with early-stage definite or probable amyotrophic lateral sclerosis (ALS).
Why this matters
ALS is incurable and has limited treatment options.
Patients in the edaravone group had a smaller reduction in Revised ALS Functional Rating Scale (ALSFRS-R) score than counterparts in the placebo group (−5.01 vs −7.50; least-squares mean difference, 2.49; P=.0013).
The rate of treatment-emergent adverse events was high and identical in the 2 groups, at 84%.
Patients in the edaravone group had a lower rate of serious adverse events (16% vs 24%) and events leading to withdrawal (1% vs 6%).